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1. Introduction
Sarcoidosis is a multi-organ, granulomatous disease of unknown etiology character-
ized by T-cell dysfunction and B-cell hyperactivity with increased local immune activ-
ity and inflammation that leads to the formation of noncaseating granulomas in the 
organs involved [1]. The lung and lymphatic system are the most commonly affected 
organs, but virtually any organ may be affected [2]. Other common sites of involve-
ment include the skin, eye, central nervous system (CNS), and the heart [3]. Patients 
may present with different symptoms related to the disease stage and the specific organ 
involved [4]. Sarcoidosis is a global disease, and its prevalence has increased twofold 
over the past years [5]. Due to the clinical heterogeneity and variable diagnostic criteria 
in different countries, it is difficult to calculate the exact prevalence and incidence of 
sarcoidosis. Age, sex, race, and geographic origin significantly influence the incidence 
rate of sarcoidosis [6]. A definite diagnosis of the disease when an identifiable etiology 
and definitive diagnostic criteria is lacking remains challenging [3].
2. Types
2.1 Head and neck sarcoidosis
This may occur in combination with, or independent of, CNS sarcoidosis; this 
has been found in 10–15% of patients with systemic disease [7].
2.2 Orofacial sarcoidosis
Although orofacial presentations of sarcoidosis are uncommon, it is important 
because of the fact that sarcoidosis in the orofacial region may indicate the develop-
ment of systemic involvement [4]. Generally, in the case of orofacial sarcoidosis, 
swelling of the salivary glands is observed. Xerostomia may or may not be present; and 
bilateral enlargement of the parotid glands may be affected in 4–6% of the cases [8].
2.3 Orofacial granulomatosis
Orofacial granulomatosis (OFG), defined by Wiesenfeld in 1985, encompasses 
conditions characterized by non-necrotizing granulomatous inflammation of soft 
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tissues in the oral and maxillofacial region that present clinically with labial enlarge-
ment, perioral and/or mucosal swelling, oral ulcerations, gingivitis, and a variety of 
other orofacial features [9]. The clinical manifestations can be highly variable, and 
this variability makes it difficult to diagnose. OFG is a disease that encompasses a 
broad range of presentations, which may include oral manifestations of a systemic 
condition such as Crohn’s disease (CD), sarcoidosis, granulomatosis with polyan-
giitis, and Melkersson-Rosenthal syndrome [10]. On the other hand, some studies 
say that OFG displays a spectrum of diseases ranging from granulomatous cheilitis 
to patients with granulomas involving other orofacial tissues, with or without facial 
nerve palsy and plicated tongue (Melkersson-Rosenthal syndrome) [11]. According 
to recent evidence, OFG can also be classified into three categories [12, 13], namely:
• OFG alone
• OFG with intestinal CD
• OFG with gastrointestinal granulomata but no symptoms of intestinal CD.
3. Etiology
The exact cause of OFG is yet to be elucidated, although various etiological 
agents have been proposed such as genetic predisposition, contact allergies, various 
microbiological agents, and immunologic causes [9]. The role of genetic predis-
position has been evaluated in different studies, but there is a lack of conclusive 
evidence between HLA and pathogenesis of orofacial granulomatosis [14–16]; there 
is no evidence to support genetics causes for OFG [16]. Because of involvement of 
OFG in CD and sarcoidosis, the possible role of infections in the pathogenesis of 
OFG has been suggested [17]. Several studies have suggested that there is no con-
clusive evidence to support the role for allergy in OFG [18]. Recently, a monoclonal 
lymphocytic expansion in OFG lesion has been identified that may be responsible 
for the granuloma formation through cytokine production in lesions [19, 20].
4. Presentation
The diagnosis of OFG is based on clinical presentation, but it can be highly vari-
able. The clinical features of OFG are mainly similar to orofacial manifestations of 
CD without apparent lesions in the bowels and may also mimic orofacial manifesta-
tions of sarcoidosis [21] labial enlargement, and sometimes oral ulcers are the main 
clinical features of OFG [22].
4.1 Lips
The lips are the most common sites of involvement in OFG. Labial swelling can 
involve the lower or upper lip or both. This feature of OFG is persistent but may 
eventually become recurrent. Each episode in this inflammatory process usually 
lasts several weeks to months [23]. The swelling varies in consistency from soft to 
rubbery [24].
4.2 Oral lesions
Three types of oral ulcers may occur in OFG as follows [25]:
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• Chronic and deep ulcers in the buccal or labial vestibules with surrounding 
raised borders (most common).
• Superficial aphthous-like ulcers on any oral mucosal surface (less common).
• Pustules on the anterior gingivae and/or labial vestibules or soft palate (the 
least common).
4.3 Salivary gland
In asymptomatic patients, enlargement of the salivary glands is the first identifi-
able sign of the disease [8]. Involvement of salivary glands has been reported in the 
maxillofacial region that xerostomia or bilateral parotid swelling is the result of 
this involvement [26, 27]. Inflammation of salivary glands differentiates OFG from 
other granulomatous diseases such as cheilitis glandularis, Wegener’s granulomato-
sis, sarcoidosis, and deep fungal infections [28].
5. Diagnosis
Since sarcoidosis is a multi-organ disorder, it can be difficult to diagnose with a 
single specific diagnostic test; and also, the presence of noncaseating granulomas 
alone does not confirm the presence of the disease because many other diseases can 
cause granulomas. On the other hand, these structures can be formed in various 
disorders [29]. In as much as in most cases of sarcoidosis, oral involvement often 
appears as the first manifestation of the disease; in diagnosis, the following criteria 
are considered [30]:
• Symptomatic oral manifestations
• Clinical and radiological findings compatible with a diagnosis of systemic 
sarcoidosis
• Pathologic evidence of noncaseating granulomas in the soft tissues of the oral 
cavity
• Exclusion of other causes of oral granulomatosis by histology of oral tissue 
biopsy negative for fungus
• No clinical evidence of other granulomatous diseases.
5.1 Differential diagnosis
As mentioned above, because of the same clinical features of orofacial lesions in 
granulomatous diseases, differential diagnoses must be considered for such diseases 
and other conditions including [31]:
• Infections, including tuberculosis, syphilis, leprosy, cat-scratch disease, and 
mycosis.
• Crohn’s disease with the development of ulcers in the GI tract as the main 
manifestation.
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• Wegener’s disease, an uncommon necrotizing granulomatosis condition with 
a set of clinical manifestations with a different immunopathogenesis [32].
• Foreign body granulomas, formation of noncaseating granulomas and also 
labial and mucosal swellings with foreign bodies as the main characteristics of 
the disease [28].
• OFG, a condition that is restricted to the orofacial region (some diseases such 
as Crohn’s disease, sarcoidosis, cheilitis granulomatosa, Wegener’s granuloma-
tosis, granulomatous infections, etc. can mimic its features), specifically lip 
swelling [33].
5.2 Diagnostic tests
Due to the ambiguity and difficulty in the exact diagnosis of granulomatous dis-
eases and OFG, appropriate clinical and laboratory tests as well as radiographic and 
endoscopic investigations and also staining techniques and biopsy can be helpful to 
differentiate between such diseases.
Useful evaluations for differentiating granulomatous diseases include, as follows [28]:
• Biopsy: useful for the correct diagnosis.
• Microscopic investigations: for detection of granulomatous inflammation.
• Special stains: used to rule out deep fungal infections and bacterial infections.
• Polarized light microscopy: for identification of foreign bodies in the tissues.
• Chest radiography and assessment of serum levels of angiotensin-converting 
enzyme (ACE); complete blood count, erythrocyte sedimentation rate (ESR), 
and serum levels of folic acid, iron, and vitamin B12; and tuberculin skin test 
are done to assess whether a systemic disease is responsible for the granuloma-
tous inflammation or not.
• Gastrointestinal evaluation is essential, especially in the presence of signs of 
anemia and intestinal malabsorption.
OFG: Blood tests, hemoglobin, C-1 esterase inhibitor, serum iron and transfer-
rin, chest X-ray, and GI endoscopy/histopathology should be normal, and tubercu-
lin skin test, PAS reaction and Ziehl-Neelsen stain, and polarized light microscopy 
for identification of foreign body materials should be negative. Also, noncaseating 
inflammation as well as elevated IgG and serum angiotensin-converting enzyme 
(ACE) levels are seen in this disease.
Crohn’s disease: There are GI symptoms, decreased vitamin B12 and ferritin 
and increased CRP. Blood test, abdominal radiography, endoscopy, and colonoscopy 
should be considered.
Sarcoidosis: There are clinical symptoms, anemia, and also increased ESR, CPR, 
serum ACE, serum, and urinary calcium in sarcoidosis patients. Chest radiograph as 
well as negative microbial culture and negative staining are also helpful in diagnosis.
Wegener’s granulomatosis: Clinical symptoms, vasculitis, and necrotizing 
granulomatosis are seen in this disease. Chest and sinus radiography as well as 
kidney function test anti-neutrophil cytoplasmic antibody (ANCA) and ESR should 
be done.
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Tuberculosis: Caseating granuloma is seen in the disease. Ziehl-Neelsen stain-
ing, chest X-ray, PPD, and PAS test are used for diagnosis.
Leprosy: Granulomatous inflammation is present in this disease, and for more 
accurate diagnosis, PAS and acid-fast staining are done.
Foreign body granulomas: Noncaseating granulomatosis and foreign bodies are 
evident in this disease.
Cheilitis granulomatosa (CG): There is no evidence of GI involvement. Blood 
tests, chest radiography, and acid-fast staining should be done. Serum calcium and 
ACE and ESR are checked.
5.3 Histopathology
Histopathologic evaluation is one of the useful methods in OFG diagnosis. 
Several studies have demonstrated that OFG and Crohn’s disease are similar with 
regard to their orofacial features and histopathology or may be similar to other 
granulomatous diseases; so it can be said that OFG is a diagnosis of exclusion [22]. 
Therefore, other complementary techniques like special stains for fungal infections 
or Ziehl-Neelsen for bacterial infections, negative microbial culture for sarcoidosis, 
etc. should be done to exclude other causes of granulomatous conditions.
Histopathological evidences indicate that in OFG lesions, noncaseating granulo-
mas may not be present in all cases (from 43 to 82%) [11, 34–37] (Figures 1 and 2). 
Dilated lymphatics, edema of corium, slight fibrosis, with/without multiple noncase-
ating granulomas with Langerhans giant cells, and lymphocytes may be seen in OFG 
lesions [11] (Figures 3 and 4).
5.4 Treatment of OFG
The definite treatment of the disease in the lack of a causative factor remains to 
be elucidated. The first line in treatment is the use of local or systemic corticoste-
roids or both. Corticosteroids are effective in reducing facial swelling and prevent-
ing recurrence. Patients with mild swelling are treated locally [35]. Atrophy and 
hypopigmentation are the only side effects of local treatment, but side effects in the 
use of corticosteroids systemically are more important and must be avoided because 
of chronicity and recurrence of the disease and long-term nature of complications 
[38]. The use of triamcinolone 10 mg/ml is also often suggested in the treatment of 
local swellings of the lips [39].
Figure 1. 
Noncaseating granulomas of sarcoidosis in skin (H&E low power).
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Other suggested treatments for OFG in the literature include hydroxychloro-
quine [35, 40], methotrexate, clofazimine [35], metronidazole, minocycline [41] 
alone or in combination with oral prednisone, thalidomide [42, 43], dapsone, and 
danazol. Surgery may be used in cases that do not respond to medical treatment. 
Altogether, a good prognosis is predicted for OFG.
5.5 Prognosis
The pattern of onset in orofacial sarcoidosis in patients determines the course 
and prognosis of the disease and also therapeutic effects after treatment [44], 
Figure 2. 
Confluent noncaseating granulomatosis of sarcoidosis.
Figure 3. 
Asteroid bodies and multinucleated giant cells in sarcoidosis.
7Introductory Chapter: Orofacial Sarcoidosis and Noncaseating Granulomatosis
DOI: http://dx.doi.org/10.5772/intechopen.83364
although affected patients may have a variety of nonspecific symptoms or may be 
asymptomatic. Oral involvement has been considered as the initial feature of the 
disease [45]. Although orofacial features in this disease are rare, a wide range of 
presentations indicates development of systemic involvement in present or future, 
so it must be considered. This disorder usually appears in the second and third 
decades of life [46] with no known racial predilection. In addition, it should be 
taken into consideration that women are more susceptible than men in this disease 
[47]. Moreover, death from sarcoidosis is a rare phenomenon except in special 
circumstances such as terminal fibrosis in the lungs, heart, or CNS [48]. Many 
patients with sarcoidosis (two-thirds) generally have a remission within a decade 
after diagnosis, with or without consequences.
6. Discussion
OFG is a rare disorder with unknown etiology. As mentioned, there are a variety 
of causative agents for OFG; but according to the accumulating data, there is no 
conclusive scientific evidence for the role of genetic susceptibility to the disease 
in the literature; so in this context, further studies are necessary [49]. Because of 
histopathological and clinical overlap in oral lesions of granulomatous diseases 
such as Crohn’s disease, sarcoidosis, CG, foreign body granulomas, tuberculosis, 
etc. [50, 51], there is a controversial question between clinicians and pathologists 
that whether the formation of granulomas in the oral lesions is a distinct disease or 
just a feature of a systemic disease. OFG patients should be monitored for all of the 
symptoms in order to strengthen the possibility of OFG by exclusion of additional 
symptoms [28].
6.1 Organ involvement
Sarcoidosis is a multisystem disorder that may affect any organ system such 
as the lungs, lymph nodes, skin, eyes, liver, heart, and nervous, musculoskeletal, 
renal, and endocrine systems [52]. The lungs are the site of involvement and 
Figure 4. 
Asteroid bodies and multinucleated giant cells in sarcoidosis (High-power view).
Sarcoidosis and Granulomatosis - Diagnosis and Management
8
granuloma formation [52]; 90% of patients have clinical manifestation of sarcoid-
osis in the lungs [53]. Oral involvement has been considered as the first feature of 
the disease although intraoral presentations of sarcoidosis and also tongue sarcoid-
osis are particularly rare and uncommon [54]. Sarcoidosis signs and symptoms 
vary depending on which organs are affected and also the stage of the disease [4].
6.2 Disease course
Disease course of sarcoidosis is usually favorable. Patients with asymptomatic 
organ involvement have a high rate of spontaneous resolution that often happens 
within 6 months of onset [3, 55]. Every 3 months in the first year after diagnosis, 
follow-up visits need to be carried out and after that once a year for 3–5 years in 
patients without problems [3, 56, 57]. In patients having a disease course that is 
progressive, immunosuppressive treatment is recommended. Long-term cortico-
steroids in patients must be limited because of major problems such as obesity and 
development of complicated metabolic syndrome [56, 58]. Mortality in sarcoidosis 
is low [59].
6.3 Diagnosis of exclusion
Without definitive diagnostic criteria, diagnosis of sarcoidosis requires exclu-
sion of other granulomatous diseases such as tuberculosis, Crohn’s disease, etc. [3]; 
therefore systemic disease evidence as well as compatible clinical and radiological 
abnormality, histological confirmation of noncaseating granulomas, and exclusion 
of other granulomatous diseases (that are able to present similar histological and 
clinical features) can be useful in the diagnosis [60].
6.4 Laboratory markers
Serum angiotensin-converting enzyme (ACE) is the first widely used marker 
that has been used as diagnostic and prognostic marker of sarcoidosis but has low 
specificity as a marker because of its poor predictive value [61–63]. In sarcoidosis, 
ACE is released by pulmonary endothelial cells into blood vessels to perform its 
functions. ACE is elevated in affected patients [64]. Serum ACE levels are cur-
rently considered as a marker of granuloma formation with limited sensitivity and 
specificity, and because of its limitation, it must be investigated with other markers 
in sarcoidosis. As mentioned before, ACE can be used for diagnosis and follow-up, 
but it must be correlated with clinical phenotypes and radiological findings [65]. In 
addition, several markers of inflammation that can be involved in the pathogenesis 
of the sarcoidosis have also been reported, which include lysozyme, cytokines, 
chemokines, and various molecules produced by activated macrophages or lympho-
cytes [66–68].
6.5 Pattern of onset
Sarcoidosis have been known as a time-limited disease with disease course of 
1–3 years in half of the patients, less than 5 years in most remaining cases, and 
rarely for decades [69].
Abrupt onset is the characteristics of acute sarcoidosis, while chronic sarcoidosis 
has a progressive onset. According to the annual organ screening tests, most types 
of organ involvement in sarcoidosis occur within 2 years of the onset of disease 
[70]. For treatment and prognosis of sarcoidosis, mode of onset is one of the most 
valid factors [71].
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6.6 Treatment outcome
Appropriate decision for treatment in sarcoidosis is difficult especially in 
the absence of a causative agent. Sarcoidosis treatment is proposed on the basis 
of prevalence of asymptomatic organ involvement, rate of spontaneous resolu-
tion, and complications of long-term corticosteroids therapy [3, 56]. There is a 
general rule that if only organ function is threatened, organ involvement should 
be treated [56, 57, 69]. Laboratory testing, biopsy, imaging studies, physical 
examination, and any other diagnostic tests are required before any treatment. 
For example, pulmonary function tests and stress testing are required before any 
treatment for pulmonary sarcoidosis [56]. Corticosteroid therapy is considered 
the first line in treatment for acute and chronic sarcoidosis and may be used 
alone or with other medications [57, 72]. Treatment of sarcoidosis is variable 
between asymptomatic cases and severe cases with systemic corticosteroid 
therapy [4]. For patients with neurological or ocular involvement or progres-
sive respiratory disease, systemic therapy is prescribed [4]. Immunosuppressive 
combination therapy is the second line in treatment of sarcoidosis in order to 
limit the corticosteroid dose [55]. Accumulating evidence suggests that systemic 
corticosteroids should be used for at least 6 months and then should be reduced 
gradually [57].
7. Conclusion
OFG is an uncommon immunologically mediated disorder with unknown eti-
ology that affects the soft tissues of the oral and maxillofacial region. Although 
the precise cause of OFG is still unknown, allergy, infection, and genetic pre-
disposition as well as immunological reaction have been suggested as probable 
causes that can be effective in pathogenesis of OFG. Clinical features of OFG are 
nonspecific, and various presentations in disease make it difficult to diagnose, so 
a comprehensive clinical, laboratory, and microscopic evaluation is required for 
exact diagnosis and treatment [28]. A number of granulomatous disorders, such 
as deep fungal infections, tuberculosis, angioedema, leprosy, Wegener’s granu-
loma, Crohn’s disease, and sarcoidosis, are similar to OFG in clinical features 
specifically persistent lip swelling, so differential tests are needed for diagnosis 
of OFG [33]. Because of similarity between OFG and some of the granulomatous 
diseases, this point arises that whether or not OFG is a distinct clinical disorder 
[12]. In this context, further studies are needed to differentiate OFG from this 
group of disorders.
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